EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Aprepitant use during chemotherapy and association with survival in women with early breast cancer

Edoardo Botteri iD, Sarah Hjorth iD, Fabio Conforti iD, Vincenzo Bagnardi, Bettina K Andreassen iD, Nathalie C Støer iD, Sameer Bhargava iD, Giske Ursin iD, Sara Gandini iD, Erica K Sloan iD, Aeson Chang iD

JNCI: Journal of the National Cancer Institute · 2025

DOI: 10.1093/jnci/djaf178 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2025. Verfasst von Edoardo Botteri und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway. Hauptthemen laut MEDLINE: Aprepitant, Breast Neoplasms, Antiemetics, Nausea. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Helse-Sør Øst, Wellcome Trust, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Preclinical studies have shown that aprepitant, an antiemetic used to prevent chemotherapy-induced nausea and vomiting, slows mammary tumor growth and progression. Here, we evaluated the association between aprepitant and survival in a large cohort of women with early breast cancer.

Methods

Using linked nationwide registry data, we identified 13 811 women diagnosed with early breast cancer between 2008 and 2020 in Norway, who received chemotherapy and antiemetics. Women were followed for metastasis and death from 1 year after diagnosis until the end of 2021. To evaluate the association between aprepitant use and distant disease-free survival (DDFS) and breast cancer-specific survival (BCSS), we used Cox regression models, controlling for tumor and patient characteristics, chemotherapy regimens, and use of other antiemetics.

Results

During chemotherapy, 7047 (51%) women were supplied with aprepitant. Overall, aprepitant use was associated with better DDFS (HRDDFS = 0.89; 95% CI = 0.79 to 1.00) and BCSS (HRBCSS = 0.83; 95% CI = 0.71 to 0.97). The survival advantage was specific to women with non-luminal breast cancer (HRDDFS = 0.69; 95% CI = 0.56 to 0.83; HRBCSS = 0.64; 95% CI = 0.51 to 0.81) and was strongest in women with triple negative breast cancer (TNBC) (HRDDFS = 0.66; 95% CI = 0.53 to 0.83; HRBCSS = 0.61; 95% CI = 0.47 to 0.80). In women with non-luminal breast cancer, longer durations of aprepitant use were associated with increasingly favorable survival outcomes (DDFS: Ptrend = .002; BCSS: Ptrend = .016). Supply of other antiemetics of different drug classes was not associated with survival.

Conclusions

Aprepitant use during chemotherapy treatment was associated with better prognosis for women with non-luminal early breast cancer, in particular TNBC. Long-term clinical trials are required to confirm these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AprepitantBreast NeoplasmsAntiemeticsNauseaAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMiddle AgedAgedNorwayAdultVomitingRegistriesDisease-Free Survival

Substanzen

AprepitantAntiemetics

Autor:innen und Institutionen

  • Department of Research, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway.
  • Department of Colorectal Cancer Screening, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway.
  • Department of Medical Oncology, Humanitas Gavazzeni, Bergamo, Italy.
  • Department of Biomedical Sciences, Humanitas University, Milan, Italy.
  • Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy.
  • Department of Oncology, Akershus University Hospital, Lørenskog, Norway.

ORCID-Profile: Edoardo Botteri, Sarah Hjorth, Fabio Conforti, Bettina K Andreassen, Nathalie C Støer, Sameer Bhargava, Giske Ursin, Sara Gandini, Erica K Sloan, Aeson Chang

Förderung

  • Helse-Sør Øst
  • Wellcome Trust
  • National Health and Medical Research Council
  • Cancer Council Victoria Grants-In-Aid
  • Kreftforeningen

Zitieren

APA

Botteri, E., Hjorth, S., Conforti, F., Bagnardi, V., Andreassen, B. K., Støer, N. C., Bhargava, S., Ursin, G., Gandini, S., Sloan, E. K., & Chang, A. (2025). Aprepitant use during chemotherapy and association with survival in women with early breast cancer. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djaf178

Vancouver

Botteri E, Hjorth S, Conforti F, Bagnardi V, Andreassen BK, Støer NC, et al. Aprepitant use during chemotherapy and association with survival in women with early breast cancer. JNCI: Journal of the National Cancer Institute. 2025. doi:10.1093/jnci/djaf178

BibTeX
@article{Botteri2025,
  author = {Botteri, Edoardo and Hjorth, Sarah and Conforti, Fabio and Bagnardi, Vincenzo and Andreassen, Bettina K and Støer, Nathalie C and Bhargava, Sameer and Ursin, Giske and Gandini, Sara and Sloan, Erica K and Chang, Aeson},
  title = {Aprepitant use during chemotherapy and association with survival in women with early breast cancer},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2025},
  doi = {10.1093/jnci/djaf178}
}
Kostenlos starten →